Singapore is a regional hub for trade and innovation, offering a strategic gateway to the fast-growing Indo-Pacific market. It has world-class research infrastructure, strong intellectual property (IP) protections, and pro-innovation regulatory environment. Singapore offers an ideal launchpad for co-developing, piloting, and scaling high-impact healthcare solutions across Southeast Asia and beyond.
Home to over 250 MedTech companies—ranging from global MNCs to dynamic startups—Singapore boasts a vibrant ecosystem. There are more than 30 R&D centres, and annual public R&D expenditure exceeds CAD 1.4 billion. This innovation landscape is underpinned by Singapore’s Research, Innovation and Enterprise (RIE) 2025 Plan, which prioritizes Human Health and Potential as one of four national focus areas. Combined with a rapidly ageing population and a digitally integrated healthcare system, Singapore offers strong local demand and collaborative opportunities across clinical, academic, and commercial spheres.
SWITCH (Singapore Week of Innovation and Technology) 2025 will serve as a flagship platform for showcasing global healthtech and biomedical innovation, connecting Canadian companies with investors, hospitals, corporates, and government stakeholders. This year’s edition carries special significance as Singapore celebrates 60 years of independence (SG60)—offering a timely moment to deepen bilateral innovation ties. Notably, health and biomedical technology is one of the four key themes of SWITCH 2025, alongside sustainability, advanced manufacturing, and digital solutions, underscoring Singapore’s national focus on health and life sciences. For Canadian innovators, SWITCH presents a high-impact opportunity to explore co-development partnerships, tap into strong local demand, and scale solutions across Southeast Asia and the Indo-Pacific region.
